期刊文献+

可逆型质子泵抑制剂的全球专利情况概述

Review of Global Patent Filing for Reversible Proton Pump Inhibitors
原文传递
导出
摘要 为了帮助国内制药企业更全面地了解全球可逆型质子泵抑制剂的专利现状,为后续研发指引方向,进一步增加国内相关制药企业的核心竞争力,运用专利情报分析方法,依据检索所得数据,对全球的可逆型质子泵抑制剂相关专利申请趋势、区域分布以及主要申请人进行了分析,并进一步就可逆质子泵抑制剂的技术生命周期作了分析。通过专利分析,可初步了解该领域的重要申请人以及相应的地域分布情况,指引国内企业根据自身研发计划以及市场规划,提早进行专利战略布局,为抢占市场做好准备。 In order to help domestic pharmaceutical companies to fully understand the status of patents on reversible proton pump inhibitors(RPPIs), give directions for the follow-up researches, and enhance market competitiveness, this paper analyzed the application trends, regional distribution and major applicants of RPPIs-related patents as well as the technology life-cycle of RPPIs by using patent intelligence analysis method and retrieved data. Through patent analysis, preliminary information about important applicants and the corresponding geographical distribution can be obtained as a guidance for domestic enterprises to carry out patent strategic layout in advance according to their own R&D plans and market planning, and to expand their market share.
作者 杨晓莉 肖明芳 王艳丽 宗在伟 郭晓敏 YANG Xiaoli;XIAO Mingfang;WANG Yanli;ZONG Zaiwei;GUO Xiaomin(Nanjing Sugao Patent and Trademark Firm,Nanjing 210005,China;Jiangsu Aosaikang Pharmaceutical Co.,Ltd.,Nanjing 211112,China)
出处 《药学进展》 CAS 2018年第12期952-955,共4页 Progress in Pharmaceutical Sciences
关键词 酸相关性疾病 可逆型质子泵抑制剂 全球专利分析 acid-related disease reversible proton pump inhibitor global patent analysis
  • 相关文献

参考文献1

二级参考文献28

  • 1石志敏,赵茹茜.质子泵与胃酸分泌的研究进展[J].畜牧与兽医,2005,37(1):50-52. 被引量:1
  • 2NIKLASSON A,LINDSTRM L,SIMRN M,et al.Dyspepticsymptom development after discontinuation of a proton pump in-hibitor:a double-blind placebo-controlled trial[J].Am J Gastro-enterol,2010,105(7):1531-1537.
  • 3KISHOR SJ,ANAMIK KS,JITENDER B,et al.Recent ad-vances in proton pump inhibitors and management of acid-pepticdisorders[J].Bioorg Med Chem,2007,15(3):1181-1205.
  • 4KEIICHI I,KAZUYA K,ATSUYUKI T.et al.The effect ofsubchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimeth-yl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine(CS-526),a novel acid pump antagonist,on gas-tricacid secretion and gastrin levels in rats[J].JPET,2008,326(1):163-170.
  • 5MALINOWSKA DH,SHERRY AM,TEWARI KP,et al.Gas-tric parietal cell secretory membrane contains PKA-and acid-acti-vated Kir2.1 K+channels[J].Am J Physiol Cell Physiol,2004,286(3):495-506.
  • 6LAMBRECHT NW,YAKUBOV I,SCOTT D,et al.Identifica-tion of the K efflux channel coupled to the gastric H+,K+AT-Pase during acid secretion[J].Physiol Genomics,2005,21(1):81-91.
  • 7WALLMARK B,JARESTEN BM,LARSSON H,et al.Differen-tiation among inhibitory actions of omeprazole,cimetidine,andSCN-on gastric acid secretion[J].Am J Physiol,1983,245(1):67-71.
  • 8JAUNIN P,HORISBERGER JD,RICHTER K,et al.Process-ing,intracellular transport,and functional expression of endoge-nous and exogenousα-β3 Na+,K+-ATPase complexes in Xeno-puso ocytes[J].J Biol Chem,1992,267(1):577-585.
  • 9LAURENCE V,JEAN MR,ERIK G.Fourier transform infraredspectroscopy study of the secondary structure of the reconstitutedneurospora crassa plasma membrane H+,K+-ATPase and of itsmembrane-associated proteolytic peptides[J].J Biol Chem,1995,270(30):17685-17696.
  • 10LI W,YANG Y,TIAN Y,et al.Preparation and in vitro/in vivoevaluation of revaprazan hydrochloride nanosuspension[J].Int JPharm,2011,408(1-2):157-162.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部